PTGFR and pachyonychia congenita: Recent massive strategies provide large amounts of data of novel biomarkers, such as PTGFR, NREP, SCARNA22, DOCK9, FLVCR2, IK2F3, USP13, and CLASP1, as potential biomarkers to predict PC progression [14], or YWHAZ in PC aggressiveness [15].